TickerGraveyard
TickerGraveyard

SYRA

Delisted
Syra Health Corp

SYRA — Post-Mortem

Syra Health Corp, a Delaware-based healthcare company, was initially registered in 2021 and traded under the symbol SYRA on the OTCQB. The firm aimed to provide innovative health solutions, carving out a niche in a competitive sector. Syra experienced a peak in interest during its early years, buoyed by substantial investments and optimistic market projections. However, by March 2026, the company disclosed disappointing financial results for the fourth quarter of 2025. Notably, the 8-K filing on March 12, 2026, indicated persistent operational difficulties that cast doubts over its ability to sustain its business model. Consequently, SYRA was delisted, a move reflecting broader vulnerabilities in managing its financial obligations. Syra's decline illustrates the risks inherent in emerging,

Syra Health Corp was delisted from the OTCQB following operational challenges and financial underperformance disclosed in its 2026 filings.

Could I Have Seen This Coming?

No structured pre-delisting signals found in our records. Absence of signals does not imply absence of risk.

Post-Mortem Analysis

Five-section narrative grounded in primary filings and contemporaneous reporting.

Origin

Syra was established with ambitions of revolutionizing healthcare delivery, focusing on innovative health solutions from its headquarters in Carmel, Indiana.

Peak

The company marked its peak with increased visibility and investment inflows post-initial registration, appearing to capitalize on a growing public interest in health technologies.

Turning Point

The critical turning point was the release of financial results for Q4 2025 in the 8-K filed on March 12, 2026, which disclosed operational challenges and losses, undermining investor confidence.

End

By the end of the reporting period, as a result of the disclosed financial distress and inadequate operational performance, Syra Health Corp was officially delisted.

Impact

Syra Health Corp's delisting from the OTCQB hindered its ability to raise capital and attract new investors, impacting its operational viability.

Lessons for Today's Investors

Transferable patterns identified from this case, written as research-report observations.

  1. 1

    Operational transparency is critical; timely disclosures can mitigate investor risks.

  2. 2

    Relying heavily on optimistic forecasts without robust operational backing can jeopardize financial stability.

  3. 3

    Company growth must be anchored in sustainable revenue models to avoid delisting.

Frequently Asked Questions

What precipitated the delisting of Syra Health Corp?
The delisting was primarily due to disappointing financial results and operational challenges disclosed in their 8-K filing on March 12, 2026.
What were the financial conditions noted in the last report?
The financial results for Q4 2025 indicated net losses and operational difficulties that raised concerns about the company's sustainability.
When did Syra Health Corp originally register, and when did it peak?
Syra Health Corp was originally registered in 2021 and peaked shortly thereafter with increased visibility and investor interest.
What implications does delisting have for company operations?
Delisting impacts a company's ability to raise capital, diminishes its market presence, and often leads to decreased stakeholder confidence.
Was Syra Health Corp an emerging growth company?
Yes, Syra Health Corp indicated its status as an emerging growth company in its filings.

Source Filings

Every fact on this page is anchored to a primary SEC filing or regulatory record. Open any source to verify against the original document.

Narrative sections on this page are AI-assisted summaries of the filings linked above. All content is reviewed against primary sources; if you find an error, the canonical record is always the linked filing.

Categories:

Industries:

Tags:

Related tickers:

Share: